It's partially a transient problem: mRNA vaccines is new technology that has never seen commercial use, so it's expected that initially you'll have production c

It's partially a transient problem: mRNA vaccines is new technology that has never seen commercial use, so it's expected that initially you'll have production capacity problems. (Not to say that countries should not prepare for future pandemics.)